Clinical studies on plasma fibronectin and factor XIII; with special reference to hyperlipoproteinemia.
When compared to age-matched normal weight normolipidemic control subjects, plasma factor XIII, plasma fibronectin and serum cholinesterase levels were found to be markedly decreased in patients with decompensated cirrhosis of the liver, not significantly changed in hyperlipoproteinemia type IIa (heterozygous subjects) and increased in hypertriglyceridemic subjects (type IIb and IV) as well as in hyperlipidemic nephrotic patients. A possible accelerated hepatic synthesis of certain plasma proteins including factor XIII and fibronectin in patients with the nephrotic syndrome as well as in endogenous hypertriglyceridemia is envisaged. It is also considered that mural thrombi, richer in factor XIII and fibronectin, would be more resistant to fibrinolysis and more readily attached to subendothelial structures.
D000328:Adult; D000941:Antigens / Q000032:analysis; D005169:Factor VIII / Q000032:analysis / Q000276:immunology; D005176:Factor XIII / Q000032:analysis*; D005260:Female; D005353:Fibronectins / Q000097:blood*; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood*; D008103:Liver Cirrhosis / Q000097:blood; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000097:blood; D014841:von Willebrand Factor
D000941:Antigens; D005353:Fibronectins; D014841:von Willebrand Factor; D005169:Factor VIII; D005176:Factor XIII